trikafta drive strong
rev beat strong trikafta launch
top-line guidanc ahead cost in-line pipelin
remain track aatd kidney crispr on-track
expect higher strong trikafta launch
top-line bottom-lin beat revenu three establish cf
convers patient trikafta trikafta beat lead
overal top-line beat vs con ep beat vs
consensu management provid guidanc includ total revenu
vs con non-gaap sg non-gaap
effect tax rate
takeaway call management highlight revenu includ
stock associ trikafta launch management assum
addit inventori build guidanc guidanc management
emphas follow management expect growth ex-u cf sale given
recent ex-u reimburs agreement management achiev ii guidanc
account trikafta persist complianc dynam estim
base management experi vertex previou cf product iii management
anticip gross-to-net discount iv expens management expect
increas driven develop pipelin product includ gene
therapi diabet tax rate management expect q/q variabl rate
peak trikafta launch management believ attain access
similar cf medicin see capac
constraint initi worri could slow uptak management expect eu trikafta
approv thu management includ minim trikafta revenu
eu guidanc management announc move cell
therapi diabet clinic studi late comment
poc studi similar gene therapi studi wherein
compound evalu directli rel small number patient
circumv hv studi rel short durat regard
endpoint management clarifi includ limit glucos
level hypoglycem episod recal program management
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
opportun employ treatment nake islet cell alon
target renal transplant recipi well islet cell incorpor
devic develop semma protect islet cell immun
reaction program management acknowledg low diagnosi rate
coupl rel low treatment rate due limit treatment
option mention attempt increas awar diseas
engag foundat addit management believ vertex
corrector molecul prove therapeut lead expans
diagnost rate well increas treatment rate management reiter
announc data aatd studi management would
provid narrow timelin deep dive aatd see note
pain manag program management focus identifi optim
candid molecul possess favor pk dose
qd bid ii administ with/without food
taken right surgic procedur iii support drug-drug-
interact profil iv accept cog
trikafta launch pipelin progress remain key driver
robust launch perform quarter solid guidanc investor
worri trikafta convers dynam satisfi
strong year revenu growth continu view vertex
top larg cap growth stock biotech look forward pipelin
progress especi aatd
trikafta uptak life-cycl manag oper margin drive risk-reward
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
trikafta penetr us
assum life-cycl extens extend
franchis also assum
penetr tripl therapi us
eu het/min
homozygot patient ww sale
cf aatd us eu
commerci success key
trikafta penetr us
assum mainten key cf franchis
life-cycl extens also assum
penetr tripl combin
homozygot heterozygot us
eu risk-adjust peak ww sale
cf aatd
ow vertex see vertex
clear leader cf therapi believ
manag potenti deliv
ep overtim
efcaci data aatd mice model
suggest efcaci corrector
human therefor model includ
risk-adjust revenu corrector
believ potenti
competit cf believ vertex
signic advantag posit
on-market drug treat cf
popul model share
competitor long-term
view descript risk reward theme
trikafta penetr us
penetr us eu total
peak ww sale cf aatd
therapi peak
trikafta cf ema approv eu
preclin compound advanc two new compound
 aatd data updat phii studi patient
 fsg initi poc phii studi focal
 hemoglobinopathi data updat phi/ii
main driver vertex uptak
current therapi orkambi/kalydeco/trikafta
development/uptak corrector
china india
view explan region hierarchi
research highest favor quintil
competitor drug fail clinic fail achiev
trikafta penetr fall short expect
kalydeco sale fail meet expect
data clinic candid
data competit exce
clinic trial nda ling
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
